The FDA assessed the security and effectiveness of atidarsagene autotemcel depending on information from 37 kids who been given atidarsagene autotemcel in two solitary-arm, open-label scientific trials and in an expanded access application.[7] Youngsters who received remedy with atidarsagene autotemcel had been in comparison to untreated youngsters